medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2018, Number 2

<< Back Next >>

Alerg Asma Inmunol Pediatr 2018; 27 (2)

Severe combined immunodeficiencies, rare or subregistered diseases?

Saucedo AAG, Espinosa PSE, González SME, Medina TEA

Language: Spanish
References: 12
Page: 37-43
PDF size: 174.08 Kb.


ABSTRACT

Background: SCID is part of the PID group and it’s considered the most severe and rare, which leads to SCID be likely underestimated or underdiagnosed. Objective: To know the current situation in Mexico regarding the report of new cases with diagnosis of SCID. Material and methods: The reported for five years in SAEH of SCID patients was searched electronically to compare it with LASID Mexico in the same period of time. In order to know which of the two registers came closest to the number of new cases diagnosed in a year, we chose to collect all the cases referred with SCID to the CNR-IDP, for almost a year. Results: We found that the cases of SCID reported by LASID are tripled compared to the SAEH reports. Regarding the patients referred to the CNR-IDP, it was established that the number of cases was closer to the reports per year of LASID, establishing a diagnostic delay of 5.5 months on average. Conclusion: The incidence of SCID in México is affected by underdiagnosed and underreporting of the disease.


REFERENCES

  1. Berman JJ. What are the rare diseases, and why do we care? Rare diseases and orphan drugs. 1. San Diego Ca. USA: Elsevier, 2014, pp. 3-7.

  2. Hernández-Blas M, Orozco-Martínez S, Contreras-Verduzco A, Medina-Torres E, Espinosa-Padilla S. ¿Cuándo sospechar de la inmunodeficiencia combinada grave en niños? Alerg Asma Inmunol Pediatr. 2014; 23: 20-26.

  3. European Society for Immunodeficiencie. Working definitions for clinical diagnosis of PID. ESID Registry 2014, p. 6.

  4. Contreras-Verduzco F, Morales-Vázquez A, Medina-Torres E, Espinosa-Padilla S. Diagnóstico oportuno de la inmunodeficiencia combinada grave (SCID) a través del tamiz neonatal. Alerg Asma Inmunol Pediatr. 2014; 23: 48-56.

  5. Mazzucchelli JT, Bonfim C, Castro GG, Condino NA, Costa NM, Cunha L et al. Severe combined immunodeficiency in Brazil: management, prognosis, and BCG-associated complications. J Investig Allergol Clin Immunol. 2014; 24: 184-191.

  6. van der Spek J, Groenwold RH, van der Burg M, Joris M. van Montfrans J. TREC based newborn screening for severe combined immunodeficiency disease: a systematic review. J Clin Immunol. 2015; 35 (4): 146-430.

  7. Gennery A, Cant A. Diagnosis of severe combined immunodeficiency. J Clin Pathol. 2001; 54: 191-195.

  8. Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol. 2015; 39: 194-205.

  9. Rezaei N, Bonilla FA, Sullivan KE, De Viries E. An introduction to primary immunodeficiency diseases. 1. Boston Ma, USA: Springer, 2008, pp. 1-29.

  10. Latin American Association of Immunology. www.lasid.org. [En línea] LASID, 2017. Available in: https://registrolasid.org/docs/Estatisticas_LASID-2017_Junio.pdf.

  11. Secretaría de Salud. www.dgis.salud.gob.mx. [En línea] 2017. Disponible en: http://www.dgis.salud.gob.mx/contenidos/basesdedatos/da_recursos_gobmx.html.

  12. Secretaría de Salud. http://www.dgis.salud.gob.mx. [En línea] 2010-2015. Disponible en: http://www.dgis.salud.gob.mx/contenidos/basesdedatos/da_egresoshosp_gobmx.html




2020     |     www.medigraphic.com